Writing and Implementing Statistical Analysis Plans (SAPs) - Domestic and International Guidance under ICH E9

Instructor: Rita Hanover
Product ID: 702783
Training Level: Advanced
  • Duration: 90 Min

recorded version

1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section

Training CD

One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-963-2556


Read Frequently Asked Questions

This training on clinical trial Statistical Analysis Plans (SAP) will review writing, timing and specific content of the SAP in the context of FDA guidance based on ICH E9 with references to ICH E3 and E6. We will work through a sample template and discuss how to approach each section for maximum clarity and ease of interpretation at the end of a study.

Why Should You Attend:

The statistical analysis plan (SAP) is a key component of a clinical trial. It is a prospective plan of statistical methods not detailed in the Protocol. While the protocol is primarily concerned with design considerations, such as study endpoints, type of control, and treatment groups for comparison, the SAP details the statistical model, analysis populations, and other quantitative analytical aspects of the study.

In this session, we will discuss commonly included sections of the SAP in the context of FDA guidance based on ICH E9 (Statistical Principles for Clinical Trials) with references to ICH E3 (Structure and Content of Clinical Study Reports) and E6 (Good Clinical Practices). References to complete and reliable SAP templates will be provided.

Learning Objective:

At the end of the webinar, participants will understand the role of the SAP in a clinical study and be able to use one of the many available templates to construct a complete and concise SAP for their next clinical protocol. Participants who do not need to create these documents will be better able to evaluate a sponsor’s SAP for regulatory compliance.

Areas Covered in the Seminar:

  • The Dance:  Relationship between the SAP and the Clinical Protocol
  • Timing of SAP preparation: Advantages of starting early and staying on top
  • Regulatory considerations, ICH E9, E6, and E3
  • Sections of the SAP, necessary and optional
  • List of tables, formatting the tables
  • Using the template to complete your SAP
  • Integrated Safety SAP
  • Integrated Efficacy SAP

Who Will Benefit:

  • Clinical research managers
  • Project managers
  • Marketing personnel in drug or medical devices companies
  • Scientists and R&D personnel involved in evaluating efficacy of a new drug or medical device
  • Quality personnel involved in evaluating safety of a new drug or medical device
  • Documentation
  • Anyone involved in writing or implementing a SAP
  • Anyone involved in decision-making for clinical phases of drug or medical device development
  • Bio statisticians

Instructor Profile:

Dr. Hanover, has worked in clinical research for over 30 years, as a Principal Investigator for studies funded by national agencies such as NIMH, Veteran’s Affairs, and DOD as well as various private pharmaceutical and medical device companies, as a Professor teaching research methods, biostatistics, and evidence-based medicine at the University of Utah School of Medicine, a Consultant to the Utah State Department of Health, and Director of Clinical Research for Techniscan Medical Systems. She has concurrently held consulting positions for such companies as Pherin Pharmaceuticals, Utah Cancer Specialists, Montgomery-Watson Environmental Engineering, and Planned Parenthood Federation of America. She earned a Regulatory Affairs Certification (RAC) in 2006 through RAPS, and is also a member of the Society of Clinical Research Associates (SOCRA), and the American Statistical Association (AMSTAT).

Topic Background:

The primary purpose of a statistical analysis plan (SAP) is to minimize bias. It should be prepared prior to unblinding the clinical study and should clearly state the proposed methods of dealing with missing data, early withdrawals, and protocol violations, and the way in which anticipated analysis problems specific to the study will be treated. It should also include a sample layout for the data summary tables to be produced.

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
21 CFR Part 11 Compliance for SaaS/Cloud Applications - 80202SEM

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed